Lejla Vajzovic is an Ophthalmology physician affiliated with Duke University. OpenAlex indexes 211 publications with 2,810 citations (h-index 28); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2100 Erwin Rd
Durham, NC 277053941
Telephone
919-684-8111Registry record last updated 14 Jul 2011.
Clinical trials
- DEXTENZA in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia
Sponsor: Lejla Vajzovic, MD, FASRS
- Evaluation of the Heidelberg Engineering SPECTRALIS With Flex Module for In-vivo Imaging in the Supine Position
Sponsor: Heidelberg Engineering GmbH
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
28 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alcon Vision LLCProgram year202522 payments$34,606openpaymentsdata.cms.gov ↗
- Bausch & Lomb Americas Inc.Program year202510 payments$26,696openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year20259 payments$12,524openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
94.6%Antineovascularisation agents91.2%Faricimab-svoa100%Part B, office-administered≥20 patientsCorticosteroid1.6%Prednisolone Acetate100%Part D≥48 patients+ 4 more classes in this area
Cancer & immunology
4%Vascular Endothelial Growth Factor Inhibitor4%Aflibercept83%Bevacizumab17%Part B, office-administered≥24 patientsMusculoskeletal
1.2%Cyclooxygenase Inhibitor1.2%Ketorolac Tromethamine100%Part D≥37 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE
American Journal of Ophthalmology
2025 - Visualization of surgical maneuvers using intraoperative real-time volumetric optical coherence tomography
Biomedical Optics Express
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Califf, MD
Duke University
Pamela Douglas, MD
Duke University
Adrian Hernandez, MD
Duke University
John Perfect, MD
Duke University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”